Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Mary Hobart"'
Autor:
Lenard A, Adler, Julie, Adams, Jessica, Madera-McDonough, Eva, Kohegyi, Mary, Hobart, Denise, Chang, Mark, Angelicola, Robert, McQuade, Michael, Liebowitz
Publikováno v:
Journal of Clinical Psychopharmacology. 42:429-439
Centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD).Two phase 3 randomized, double-blind, placebo-controlled, parallel
Autor:
George T Grossberg, Daniel Lee, Mary Slomkowski, Nanco Hefting, Dalei Chen, Klaus Groes Larsen, Eva Kohegyi, Mary Hobart, Jeffrey L Cummings
Publikováno v:
Alzheimer's & Dementia. 18
Publikováno v:
Journal of Clinical Psychopharmacology. 40:560-567
PURPOSE/BACKGROUND Evidence supports use of adjunctive atypical antipsychotics in major depressive disorder (MDD). Impaired sexual functioning is common in MDD and may be worsened by antipsychotic adverse effects. We evaluated the effect of brexpipra
Autor:
Christoph U, Correll, Ying, He, François, Therrien, Erin, MacKenzie, Stine R, Meehan, Catherine, Weiss, Nanco, Hefting, Mary, Hobart
Publikováno v:
The Journal of Clinical Psychiatry. 83
Autor:
Eva Kohegyi, Timothy E. Wilens, Anthony McKinney, Timothy Wigal, Mary Hobart, Sharon B. Wigal, Jessica J Madera, Ross A. Baker
Publikováno v:
Neuropsychiatric Disease and Treatment. 16:1411-1426
Purpose Two phase 2 studies evaluated the efficacy and tolerability of centanafadine sustained-release (SR) for adults with attention-deficit/hyperactivity disorder (ADHD). Patients and Methods In a phase 2a, flexible-dose, single-blind study, 41 mal
Autor:
Robert D. McQuade, Jeffrey L. Cummings, Mary Slomkowski, Didier Meulien, George T. Grossberg, Victor Mergel, Mary Hobart, Eva Kohegyi, Ross A. Baker, Mette Krog Josiassen
Publikováno v:
The American Journal of Geriatric Psychiatry. 28:383-400
Objective To assess the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer's dementia (AAD). Design Two 12-week, randomized, double-blind, placebo-controlled, parallel-arm studies (NCT01862640; NCT01922258). S
Publikováno v:
Acta Neuropsychiatrica. 32:153-158
Objective:We provide a closer look at the result of a randomised, placebo-controlled, active-reference (quetiapine XR), flexible-dose, 6-week study of brexpiprazole in schizophrenia, which did not meet its primary endpoint – change from baseline in
Autor:
Stephen R, Marder, Stine R, Meehan, Catherine, Weiss, Dalei, Chen, Mary, Hobart, Nanco, Hefting
Publikováno v:
Schizophrenia Bulletin Open
The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this post hoc analysis was to characterize the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) ‘Ma
Publikováno v:
Expert Opinion on Pharmacotherapy. 20:1907-1916
Background: There is a need for effective, safe and well-tolerated pharmacotherapies for patients with major depressive disorder (MDD) who have inadequate response to antidepressant treatments (ADT...
Publikováno v:
Schizophrenia Bulletin Open. 2
The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this post hoc analysis was to characterize the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) ‘Ma